BioLineRx is trading at $2.16, up 7.46%, with no confirmed company-specific catalyst identified for the October 19 move. - The latest release on the company’s investor-relations page is dated October 8. - A patent-allowance announcement covering motixafortide surfaced October 16, but available reporting does not establish it as the cause of the move. - The broader market is firmer, with the Nasdaq up 0.96%; the rebound may be supportive, but the connection is unconfirmed.